Printer Friendly

BIOPOOL ANNOUNCES JAPANESE MINISTRY OF HEALTH AND WELFARE APPROVAL FOR DIAGNOSTIC KIT

 VENTURA, Calif., May 3 /PRNewswire/ -- Biopool International Inc. (NASDAQ: BIPL) today announced that the Japanese Ministry of Health and Welfare has granted Class 1 registration approval for the sale of its TintElize(R)Lp(a) kit in Japan for in vitro diagnostic use in hospitals, clinics and medical laboratories. For the past three years, Biopool's test kit was used in Japanese research facilities.
 Compelling evidence, collected over the past eight years, has indicated that a form of blood cholesterol called Lipoprotein(a), or Lp(a), is a major risk factor for atherosclerosis, coronary artery disease and thrombosis. This risk factor was confirmed in at least three independent studies, published recently, in which Biopool's TintElize(R)Lp(a) kit was used.
 The company's Japanese distributor, Cosmo Bio Co. Ltd. plans an extensive marketing campaign for the TintElize(R)Lp(a) kit.
 "The medical community in Japan has enthusiastically embraced Lp(a) determination in the panel of tests used for coronary artery disease," said Mats Ranby, Ph.D., Biopool's scientific director. "As a result, we expect an extremely high interest in Biopool's TintElize(R)Lp(a) test kit in Japan, and this approval hopefully will pave the way for eventual market penetration of this kit in other countries."
 Michael D. Bick, Ph.D., chief executive officer, said, "We believe that the regulatory approval of our in vitro diagnostic test kit should favorably impact sales, and as a result of this registration, our test kit will be approved for insurance reimbursement so that hospitals, clinics, etc., will be reimbursed for the cost of administering the test. This should allow Biopool's TintElize(R)Lp(a) test kit to be widely used in Japan's medical community."
 Founded in 1987, Biopool develops, manufactures and markets a full range of test kits to assess and diagnose disorders of blood coagulation, fibrinolysis, platelet function and the vascular system, as well as test kits to determine thrombotic risk factors. The company's products are sold to hospitals and clinical laboratories worldwide.
 -0- 5/3/93
 /CONTACT: Michael D. Bick, Ph.D., CEO, 805-654-0643, or Andrew L. Cerskus, Ph.D., president (Canada), 416-332-9419, both of Biopool; or Kim P. Feazle of Pondel Parsons & Wilkinson, 310-207-9300, for Biopool/
 (BIPL)


CO: Biopool International Inc.; Cosmo Bio Co. Ltd. ST: California IN: MTC SU:

BP-JL -- LA007 -- 3586 05/03/93 09:00 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 3, 1993
Words:389
Previous Article:CONDO SALES RISE AS BUYERS RESPOND TO LOW MORTGAGE RATES
Next Article:SECURITY ENVIRONMENTAL SYSTEMS ANNOUNCES $4.6 MILLION SALE OF BIOMEDICAL WASTE DIVISION
Topics:


Related Articles
BIOPOOL INTERNATIONAL INC. COMPLETES THE ACQUISITION OF MEDICAL DIAGNOSTIC TECHNOLOGIES INC.
BIOPOOL INTERNATIONAL ANNOUNCES REDUCTION IN NET LOSS FOR 1991
BIOPOOL RECEIVES FDA APPROVAL TO MARKET MINUTEX(TM) D-DIMER AND SPECTROLYSE PL/PAI TEST KITS
BIOPOOL RECEIVES TWO NEW PATENTS
BIOPOOL REPORTS THIRD QUARTER RESULTS
BIOPOOL RECEIVES FDA APPROVAL TO MARKET SPECTROLYSE(TM) VIII-C AND BIOCLOT(TM) LA
BIOPOOL REPORTS YEAR-END RESULTS
BIOPOOL REPORTS FIRST QUARTER RESULTS; EARNINGS UP THREEFOLD
BIOPOOL INTERNATIONAL RECEIVES FDA APPROVAL TO MARKET FIVE (5) NEW CHEMISTRY REAGENT SYSTEMS
Matritech's NMP22(R) Test Kit for Urothelial Cancer Receives Reimbursement for Diagnosis in Japan.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters